Theralizumab (also known as TGN1412, CD28-SuperMAB, and TAB08) is an immunomodulatory drug developed by immunologist Thomas Hünig of the University of...
38 KB (4,316 words) - 10:24, 26 August 2024
Hospital in England resulted in all 6 of the volunteers given the drug theralizumab becoming critically ill, with multiple organ failure, high fever, and...
25 KB (2,786 words) - 02:05, 24 June 2024
T cell tisagenlecleucel. The experimental drug TGN1412—also known as Theralizumab—caused extremely serious symptoms when given to six participants in a...
24 KB (2,551 words) - 01:16, 25 June 2024
Healthcare NHS Trust) became severely unwell following administration of theralizumab during a first-in-human clinical trial. They were transferred to the...
13 KB (1,264 words) - 22:00, 23 May 2024
could be used to treat several types of myeloma. anti-CD28, now named theralizumab was developed in Stevenson's laboratory, and is now the normal treatment...
8 KB (788 words) - 22:08, 22 October 2023
in recognition of his inquiry into, and report on, the conduct of a Theralizumab clinical trial at Northwick Park Hospital in March 2006. Sir Gordon was...
17 KB (1,704 words) - 11:43, 11 August 2024